Canada unlikely to hit 2030 hepatitis C elimination target: Study
Current screening and treatment strategies won’t allow Canada to eliminate new cases of hepatitis C by 2030, a population modeling study found. That’s the…
Steve Bryson, PhD, Science Writer—
Articles by Steve Bryson
Ascletis to stop clinical testing of ASC42 in primary biliary cholangitis
Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with primary biliary cholangitis (PBC). The…
Blood protein predicts post-transplant liver fibrosis in biliary atresia
A blood test that measures the levels of the M2BPGi protein accurately predicts the presence of moderate liver scarring, or fibrosis, in children and adolescents…
Phase 1b/2 trial of golexanolone for PBC behavioral symptoms advances
Golexanolone, Umecrine Cognition’s investigational oral therapy, was generally safe and well tolerated in adults with primary biliary cholangitis (PBC) and clinically significant…
Worse outcomes risk rises with liver ailment ICP, gestational diabetes
Having gestational diabetes increases the risk of adverse outcomes in pregnancy for women with intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver…
Atea’s antiviral treatment combo works for 98% of HCV patients
Note: This story was updated Aug. 22, 2024, to clarify the timeline detailing the results of treatment. Atea Pharmaceuticals’ once-daily oral antiviral treatment for…
Small amounts of alcohol deemed OK in early steatotic liver disease
Drinking a small amount of alcohol each day did not raise the mortality risk among people in the early stages of steatotic liver disease…
Gut microbiota may be noninvasive diagnostic tool in biliary atresia
The composition of microbes is altered in the intestines of infants with biliary atresia, a type of liver disease that affects the bile ducts,…
Resmetirom successfully treats NASH, reduces liver scarring in trial
One year of daily resmetirom, Madrigal Pharmaceuticals’ investigational oral therapy, was shown to successfully treat nonalcoholic steatohepatitis (NASH), a severe type of fatty liver…
FDA to review approval application for seladelpar as PBC treatment
The U.S. Food and Drug Administration (FDA) will review CymaBay Therapeutics’ application for seladelpar, an oral investigational treatment for adults with…